Search Prime Grants

W81XWH2110369

Project Grant

Overview

Grant Description
Aryl Hydrocarbon Receptor Innate Immune Modulators for Treatment of Inflammatory Bowel Disease
Awardee
Beth Israel Deaconess Medical Center
Funding Goals
PEER REVIEWED MEDICAL RESEARCH PROGRAM AWARD MECHANISM: TECHNOLOGY/THERAPEUTIC DEVELOPMENT AWARD
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding / Funding Agency
Defense Health Agency (DHA) [DoD]
Place of Performance
Boston, Massachusetts 022155400 United States
Geographic Scope
Single Zip Code
Related Opportunity
W81XWH20PRMRPTTDA
Analysis Notes
Amendment Since initial award the End Date has been extended from 05/31/25 to 05/31/26.
Beth Israel Deaconess Medical Center was awarded AHR Innate Immune Modulators for IBD Treatment Project Grant W81XWH2110369 worth $6,766,843 from Defense Health Agency in June 2021 with work to be completed primarily in Boston Massachusetts United States. The grant has a duration of 5 years and was awarded through assistance program 12.420 Military Medical Research and Development.

Status
(Ongoing)

Last Modified 10/29/25

Period of Performance
6/1/21
Start Date
5/31/26
End Date
89.0% Complete

Funding Split
$6.8M
Federal Obligation
$0.0
Non-Federal Obligation
$6.8M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to W81XWH2110369

Transaction History

Modifications to W81XWH2110369

Additional Detail

Award ID FAIN
W81XWH2110369
SAI Number
None
Award ID URI
None
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Other
Awarding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Funding Office
HT0989 CONG DIR MED RES PRGM / CDMRP - MM
Awardee UEI
C1CPANL3EWK4
Awardee CAGE
4B998
Performance District
MA-07
Senators
Edward Markey
Elizabeth Warren
Modified: 10/29/25